Pesquisa de mercado médico

Os médicos são altamente influentes no atendimento ao paciente, na tomada de decisões organizacionais e no uso de tratamentos e prescrições.

Compreender as suas opiniões, comportamentos e perspectivas pode ser muito útil para empresas de cuidados de saúde, dispositivos médicos e farmacêuticas.

Physicians are specialized medical professionals.  Clinicians on the other hand are primary care givers of a patient.  The roles of the two disciplines are often blurred. Physicians are clinicians, and the terms are commonly used interchangeably.  We will use the word “clinician” to refer to all healthcare providers who deal with patients.  “Physician” will refer to clinicians who focuses on a particular specialty.

Physician Market Research: How Leading Pharma Brands Convert Clinical Insight into Commercial Advantage

Physician market research separates pharmaceutical brands that launch on time from those that miss formulary windows. The discipline has matured. The bar has risen. Enterprise teams now expect prescriber intelligence that ties directly to launch sequencing, payer value stories, and indication prioritization decisions worth hundreds of millions in lifetime revenue.

The opportunity is sharper than most commercial leaders recognize. Brands that invest in structured prescriber intelligence early in development consistently outperform peers on time-to-peak-share. The work is not survey volume. It is mechanism: understanding why a hematologist sequences a regimen the way she does, and what evidence would change her sequencing.

What Modern Physician Market Research Actually Measures

Strong programs measure four things: clinical decision drivers, evidence thresholds, perceived product differentiation, and the unmet need that competitors have not yet addressed. Each maps to a commercial decision. Decision drivers shape sales aid design. Evidence thresholds shape phase III endpoints and HTA submission evidence. Differentiation shapes payer value story. Unmet need shapes indication prioritization.

The conventional approach treats physician research as message testing. The better approach treats it as decision archaeology. A rheumatologist prescribing an SGLT-2 inhibitor outside her primary specialty is making a referral-pattern decision shaped by cardiology guidelines, renal comorbidity prevalence, and her relationship with the local nephrology group. Surveys capture preference. Structured interviews capture the architecture behind it.

According to SIS International Research, prescriber decision pathways for cardiometabolic agents like Jardiance, Farxiga, and Ozempic show meaningful divergence between specialty cohorts even when the clinical indication is identical. Endocrinologists, cardiologists, and primary care physicians each apply different evidence thresholds, and the gap widens in markets where formulary positioning is contested.

Why Specialty Segmentation Determines Launch Sequencing

Treating prescribers as a single audience is the most expensive mistake in commercial planning. Oncology illustrates the point. A medical oncologist treating gastric cancer and gastroesophageal junction cancer evaluates perioperative regimens against tolerability, performance status, and the realistic expectation of curative intent. A community oncologist in a smaller catchment weighs the same regimen against infusion chair capacity and patient travel burden.

Both prescribe. Both matter to the brand. Neither responds to the same value proposition. Launch sequencing depends on knowing which segment carries the early adoption weight and which segment determines durable share. KOL mapping addresses the first question. Community prescriber panels address the second.

SIS International’s structured expert interviews with oncologists across the United Kingdom and United States surfaced a consistent pattern: perioperative treatment decisions in gastric and GEJ cancer hinge less on overall survival data than on tolerability signals that affect a patient’s eligibility for surgery. Brands that frame their evidence around surgical eligibility convert clinical interest into prescription behavior faster than brands that lead with survival curves.

The Methodologies That Produce Defensible Commercial Decisions

Four methodologies carry most of the analytical weight in serious physician market research programs.

Recruitment screeners determine the validity of every downstream finding. A screener that fails to control for facility type, patient volume, and prescription recency will produce confident-sounding nonsense. Programs targeting SGLT-2 inhibitor prescribers, for example, must distinguish between physicians who initiate therapy and those who continue it. The two cohorts hold different opinions and influence different commercial decisions.

Entrevistas aprofundadas remain the highest-yield instrument for understanding clinical reasoning. Sixty minutes with a prescribing hematologist produces more usable launch intelligence than three hundred survey responses, provided the moderator can follow clinical logic in real time.

Patient journey mapping with physicians, not just patients, reveals where therapy decisions are actually made. The decision point in chronic kidney disease often sits with the cardiologist, not the nephrologist. The decision point in heart failure increasingly sits with the primary care physician. Patient activation and adherence programs that miss the actual decision point fail at scale.

Quantitative validation panels convert qualitative hypotheses into payer-grade evidence. The transition from N=20 interviews to N=200 quantitative reads is where most programs lose rigor. The instrument must preserve the language physicians actually use.

Cross-Border Prescriber Research and Referral Economics

Referral patterns now carry commercial weight that rivals direct prescribing. Brazilian physicians referring complex cases to U.S. academic medical centers, European oncologists routing rare tumor patients to specialty centers, and APAC cardiologists coordinating with regional centers of excellence all generate prescription decisions that originate outside the local market.

SIS International’s proprietary research on cross-border physician referral behavior, including studies on referrals from Brazilian specialists to U.S. academic medical centers, indicates that brand image at the receiving institution shapes the referring physician’s specialty drug recommendations months before the patient arrives. The referral conversation is itself a prescribing event.

Continuing Medical Education as a Commercial Intelligence Channel

CME participation patterns are the most underused commercial signal in pharmaceutical marketing. Family physicians, physician assistants, and nurse practitioners select CME content based on the clinical questions they cannot answer in practice. That selection behavior is a leading indicator of where evidence gaps exist, and where competitor brands have failed to fill them.

Brands that map CME engagement against prescribing data identify white space before competitors do. The American Academy of Family Physicians, the American College of Cardiology, and specialty society programs each generate engagement signals worth tracking. Commercially funded CME and learner-paid CME segment differently and require separate analysis.

The SIS Physician Intelligence Framework

Source: SIS International Research

What Separates Brands That Win at Launch

Three practices distinguish brands that capture peak share quickly. They commission physician market research before phase III readout, not after. They run KOL mapping and community prescriber panels in parallel, not sequentially. They treat real-world evidence and prescriber perception as complementary inputs to formulary positioning, not as separate workstreams.

The shared characteristic is timing. Commercial teams that engage prescriber intelligence early enough to shape evidence generation outperform teams that engage it only to interpret evidence already generated. The economics favor the early movers by a wide margin in competitive therapeutic categories.

Where Physician Market Research Is Heading

Three shifts are accelerating. Hybrid methodologies that combine asynchronous video diaries with live expert interviews produce richer data at lower cost than traditional designs. Specialty-specific recruitment is migrating toward verified credential platforms, raising panel quality. And payer-prescriber convergence research, which examines how formulary decisions and prescriber preference interact, is becoming standard rather than exotic.

The brands positioning for the next launch cycle are already commissioning this work. Physician market research has become the connective tissue between clinical development, market access strategy, and commercial execution. Treated as such, it pays for itself within the first two quarters of launch.

Sobre SIS Internacional

SIS Internacional offers Quantitative, Qualitative, and Strategy Research. We provide data, tools, strategies, reports, and insights for decision-making. We also conduct interviews, surveys, focus groups, and other Market Research methods and approaches. Entre em contato conosco para o seu próximo projeto de pesquisa de mercado.